Johnson & Johnson is a diversified healthcare company organized into two primary business segments: Innovative Medicine and MedTech. The Innovative Medicine segment develops prescription drugs for oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism. Key products include CARVYKTI, DARZALEX, ERLEADA, IMBRUVICA, RYBREVANT, STELARA, TREMFYA, CAPLYTA, INVEGA, SPRAVATO, PREZISTA, OPSUMIT, UPTRAVI, and XARELTO. The MedTech segment provides medical devices for cardiovascular, orthopaedics, surgery, and vision. This portfolio includes electrophysiology and mechanical circulatory support technologies from Abiomed, circulatory restoration products from Shockwave, surgical instruments and robotic systems, breast aesthetics products from Mentor, and vision products such as ACUVUE contact lenses and TECNIS intraocular lenses. The company serves hospitals, healthcare professionals, wholesalers, and retailers in virtually all countries worldwide. Incorporated in 1887, Johnson & Johnson announced in October 2025 its intention to separate its Orthopaedics business.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Drug Manufacturers - General Homepage jnj.com
Sector Healthcare IR page jnj.com
Tags
oncology, immunology, neuroscience, cardiovascular devices, orthopaedics, surgical robotics, vision care, car-t cell therapy, anticoagulants, hiv treatment, CARVYKTI, DARZALEX, DARZALEX FASPRO, ERLEADA, IMBRUVICA, RYBREVANT, LAZCLUZE, RYBREVANT FASPRO, TALVEY, TECVAYLI, ZYTIGA, REMICADE, SIMPONI, SIMPONI ARIA, STELARA, TREMFYA, CAPLYTA, CONCERTA, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, SPRAVATO, EDURANT, PREZISTA, PREZCOBIX, REZOLSTA, SYMTUZA, OPSUMIT, OPSYNVI, UPTRAVI, XARELTO, Abiomed, Shockwave, Mentor, ACUVUE, TECNIS, OTTAVA
Press page jnj.com/media-center/press-releases

Metrics

Valuation  
Market cap $ 684.615B
Market cap (USD) $ 684.615B
P/E 43.22
PEG 3.02
P/BV 8.40
P/S 6.89
P/OCF 26.17
P/FCF 33.25
Dividend yield <0.01%
Turnover / mcap —
Returns  
ROE 35.0%
ROI 21.8%
ROIC 17.1%
Profit margin 28.5%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 14.3%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 43.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 101
Quality score 10.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 94.193B 88.821B 85.159B 94.943B 93.775B 82.584B 82.059B 81.581B 76.45B 71.89B 70.074B 74.331B 71.312B 67.224B 65.03B 61.587B 61.897B 63.747B 61.095B 53.324B 50.514B 50.514B 41.862B 36.298B 33.004B 29.139B
Net profit 26.804B 14.066B 35.153B 17.941B 20.878B 14.714B 15.119B 15.297B 1.3B 16.54B 15.409B 16.323B 13.831B 10.853B 9.672B 13.334B 12.266B 12.949B 10.576B 11.053B 10.06B 10.411B 7.197B 6.597B 5.668B 4.8B
Free cash flow 19.698B 19.842B 18.248B 17.185B 19.758B 20.189B 19.918B 18.531B 17.777B 15.541B 15.816B 14.757B 13.819B 12.462B 11.405B 14.001B 14.206B 11.906B 12.307B 11.582B 9.167B 9.245B 8.333B 6.077B 7.133B —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 206.95 144.62 156.74 176.65 171.07 157.38 145.87 129.05 139.72 115.21 102.72 104.57 91.59 70.1 65.58 61.85 64.41 59.83 67.93 66.25 — — — — — —
Price performance 12m 0.43 -0.08 -0.11 0.03 0.09 0.08 0.13 -0.08 0.21 0.12 -0.02 0.14 0.31 0.07 0.06 -0.04 0.08 -0.12 0.03 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 11.7B 13.5B 14.1B 14.5B 13.6B 15.3B 16.2B 14.9B 14.8B 17.2B
↳ YoY growth +9.0% +15.3% +4.5% +2.7% -6.2% +12.6% +5.7% -8.0% -0.2% +15.7%
↳ 5y CAGR +2.0% +3.6% +3.8% +5.7% +4.8% +5.5% +3.7% +1.1% +0.5% +4.8%
Borrowings, current (USD) 4.68B 5.41B 5.4B 1.2B 2.63B 5.9B 14.3B 4.92B 7.73B 10.5B
Borrowings, non-current (USD) 22.4B 30.7B 27.7B 26.5B 32.6B 30B 26.9B 25.9B 30.7B 39.4B
Lease liabilities (USD) — — — 985M 1.1B 1B 1.3B 1.1B 1.2B 1.4B
Cash and deposits (USD) 19B 17.8B 18.1B 17.3B 14B 14.5B 14.1B 21.9B 24.1B 19.7B
Intangible assets (USD) 26.9B 53.2B 47.6B 47.6B 53.4B 46.4B 48.3B 34.2B 37.6B 50.4B
Right-of-use assets (USD) — — — 957M 1B 900M 1.1B 1B 1.1B 1.3B
Net debt (borrowings + leases - cash) (USD) 8.15B 18.3B 15B 11.4B 22.4B 22.4B 28.4B 10B 15.5B 31.6B
Cash flow detail
Operating cash flow (USD) 18.8B 21.1B 22.2B 23.4B 23.5B 23.4B 21.2B 22.8B 24.3B 24.5B
Purchases of property, plant and equipment (USD) -3.23B -3.28B -3.67B -3.5B -3.35B -3.65B -4.01B -4.54B -4.42B -4.83B
Change in receivables (cash effect) (USD) -1.07B -633M -1.19B -289M 774M -2.4B -1.29B -624M -406M -1.78B
Change in inventories (cash effect) (USD) -249M 581M -644M -277M -265M -1.25B -2.53B -1.32B -1.13B -1.45B
Change in payables (cash effect) (USD) 656M 2.73B 3.95B 4.06B 5.14B 2.44B 1.1B 2.35B 1.62B 2.38B
Share buybacks (cash effect) (USD) -8.98B -6.36B -5.87B -6.75B -3.22B -3.46B -6.04B -5.05B -2.43B -5.95B
Interest paid (cash effect) (USD) -628M -866M -963M -925M -841M -941M -933M -1.77B -1.91B -1.86B
Income taxes paid (cash effect) (USD) -2.84B -3.31B -4.57B -4.19B -4.62B -4.77B -5.22B -8.57B -6.71B -6.54B
Share-based compensation (USD) 878M 962M 978M 977M 1.01B 1.14B 1.14B 1.16B 1.18B 1.35B
Operating cash flow before change in receivables (USD) 19.8B 21.7B 23.4B 23.7B 22.8B 25.8B 22.5B 23.4B 24.7B 26.3B
Free cash flow (OCF - PPE - intangibles) (USD) 15.5B 17.8B 18.5B 19.9B 20.2B 19.8B 17.2B 18.2B 19.8B 19.7B
Income detail
Research and development expense (USD) 9.1B 10.6B 10.8B 11.4B 12.2B 14.7B 14.6B 483M 1.84B 109M
↳ 5y CAGR +3.8% +6.6% +5.7% +6.0% +6.1% +10.1% +6.7% -46.3% -30.5% -61.1%
Total comprehensive income (USD) 14.8B 3B 13.5B 14.5B 15.4B 23.1B 18B 30.4B 14.9B 23.6B
Provision for credit losses (USD) -11M 17M -31M -20M 63M -48M -17M 0.00 11M -1M
Credit cost ratio (credit losses / average receivables) (%) 0.1% 0.1% 0.2% 0.1% 0.4% 0.3% 0.1% 0.0% 0.1% 0.0%
Reported Feb 27, 2017 Feb 21, 2018 Feb 20, 2019 Feb 18, 2020 Feb 22, 2021 Feb 17, 2022 Feb 16, 2023 Feb 16, 2024 Feb 13, 2025 Feb 11, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

· Late-breaking data from Phase 3 investigational study presented at the American College of Rheumatology Convergence show 58% of ICOTYDE-treated patients achieved an ACR20 response and 29% achieved an ACR50 response at Week 16

· ICOTYDE is a first-in-class IL-23R targeted oral peptide, demonstrating significant joint and skin improvements and a favorable safety profile in a once-daily pill

November 7, 2026

November 7, 2026

Share

New Brunswick, N.J. (November 7, 2026) – Johnson & Johnson (NYSE: JNJ) today announced positive results from a Phase 3 study investigating ICOTYDE® (icotrokinra) in biologic-naïve adults with active psoriatic arthritis (PsA).a,b ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.1 ICOTYDE met the primary endpoint, with 58% of patients achieving an American College of Rheumatology 20 (ACR20) response compared with 41% receiving placebo at Week 16.2 Safety findings were consistent with the established safety profile of ICOTYDE, with no new safety signals identified. These results are being presented as a late-breaking poster at the American College of Rheumatology (ACR) Convergence 2026.

Psoriatic arthritis is a chronic, immune-mediated inflammatory disease that can affect both the joints and skin.3,4 Nearly 30 percent of people with plaque psoriasis also develop psoriatic arthritis.5,6 It can cause pain, stiffness and swelling in and around the joints, along with the skin lesions associated with plaque psoriasis.7 Because inflammation can lead to progressive disease, there remains a need for treatment approaches that address the multiple ways psoriatic arthritis can affect patients. In clinical studies, ACR response is a composite measure whereby ACR20 represents ≥20% improvement in tender joint count, swollen joint count and other measures of disease activity. ACR50 and ACR70 use the same framework but represent ≥50% and ≥70% improvement, respectively.

“The significant joint responses observed in this study show the exciting potential for ICOTYDE, a targeted oral peptide therapy, to open an entirely new chapter in treating psoriatic arthritis with an oral option,” said Joseph F. Merola, MD MMSc, Rheumatologist, Dermatologist, President of the Psoriasis and Psoriatic Arthritis Multicenter Advancement Network, Co-President of the Group for Research in Psoriasis and Psoriatic Arthritis and President of the Rheumatologic Dermatology Society.d “Effective management of psoriatic arthritis requires addressing both joint and skin disease, and patients continue to need treatment options that can provide meaningful improvement across both.”

ICOTYDE demonstrated joint and skin improvements through Week 242

The Phase 3 ICONIC-PsA 1 study met its primary endpoint, with a significantly higher proportion of patients receiving ICOTYDE 200 mg achieving an American College of Rheumatology 20 (ACR20)c response compared with placebo (58% vs. 41%) at Week 16. Numerically higher proportions of patients receiving ICOTYDE also achieved ACR50 (29% vs. 16%) and ACR70 (13% vs. 5%). Among patients with qualifying skin involvement, 57% receiving ICOTYDE achieved clear or almost clear skin (Investigator’s Global Assessment [IGA] 0/1)e, compared with 14% receiving placebo (nominal p<0.001), while 37% achieved a Psoriasis Area and Severity Index (PASI)f score of 90 compared with 6% receiving placebo (nominal p<0.001).

Response rates with ICOTYDE 200 mg continued to increase numerically through Week 24, with 69% of patients achieving ACR20, 40% achieving ACR50, and 18% achieving ACR70. Among patients with qualifying baseline skin involvement (BSA)g, 64% achieved clear or almost clear skin (IGA 0/1) and 56% achieved PASI 90. Safety data through Week 24 were consistent with the established safety profile of ICOTYDE, with no new safety signals identified.

“Many people living with psoriatic arthritis are still searching for treatments that can effectively address the full burden of their disease,” said David M. Lee, M.D., Ph.D., Global Immunology Therapeutic Area Head, Johnson & Johnson. “These new findings underscore the potential of ICOTYDE to meaningfully improve outcomes in psoriatic arthritis and add to the growing body of evidence across psoriatic disease.”

Editor’s notes:

a. ICONIC-PsA 1 is an investigational Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of once-daily oral icotrokinra in biologic-naïve adults with active psoriatic arthritis. At Week 16, participants in the placebo group who were still on study treatment crossed over to receive ICOTYDE.
b. ICOTYDE is not approved for the treatment of active PsA.
c. American College of Rheumatology 20/50/70 (ACR20/50/70) response is defined as at least a 20%/50%/70% improvement in both tender and swollen joint counts and at least a 20%/50%/70% improvement in three of five other measures of disease activity.8
d. Dr. Joseph Merola is a paid consultant for Johnson & Johnson. He has not been compensated for any media work.
e. The Investigator’s Global Assessment (IGA) is a five-point scale with a severity score ranging from 0 to 4, where 0 indicates clear, 1 is minimal, 2 is mild, 3 is moderate, and 4 indicates severe disease.9
f. The Psoriasis Area and Severity Index (PASI) score grades the amount of surface area on each body region that is covered by psoriasis plaques and the severity of plaques for their redness, thickness and scaliness. PASI 100 corresponds to an improvement of 100% in PASI score from baseline.10
g. Patients with a baseline plaque psoriasis body surface area (BSA) ≥3% and IGA score ≥2.

About the ICONIC clinical development program

Phase 3 studies investigating ICOTYDE in active psoriatic arthritis include:

  • ICONIC-PsA 1 (NCT06878404 ) is a RCT to evaluate the efficacy and safety of ICOTYDE compared to placebo for the treatment of biologic-naïve participants with active PsA.11
  • ICONIC-PsA 2 (NCT06807424 ) is a RCT to evaluate the efficacy and safety of ICOTYDE compared to placebo for the treatment of biologic-experienced and biologic-naïve participants with active PsA.12

Pivotal Phase 3 studies in moderate-to-severe plaque psoriasis include:

  • ICONIC-LEAD (NCT06095115 ) is a RCT to evaluate the efficacy and safety of ICOTYDE compared with placebo in participants with moderate-to-severe plaque PsO.13
  • ICONIC-TOTAL (NCT06095102 ) is a RCT to evaluate the efficacy and safety of ICOTYDE compared with placebo for the treatment of PsO in participants with at least moderate severity affecting special areas (e.g., scalp, genital, and/or hands and feet).14
  • ICONIC-ADVANCE 1 (NCT06143878 ) and ICONIC-ADVANCE 2 (NCT06220604 ) are RCTs to evaluate the efficacy and safety of ICOTYDE compared with both placebo and deucravacitinib in adults with moderate-to-severe plaque PsO.15,16

Additional studies underway include: ICONIC-UC (NCT071196748 ) in moderately to severely active ulcerative colitis; and ICONIC-CD (NCT7196722 ) in moderately to severely active Crohn’s disease.17,18,19

About psoriatic arthritis

Psoriatic arthritis (PsA) is a chronic, immune-mediated, inflammatory disease characterized by peripheral joint inflammation, enthesitis (pain where the bone, tendon and ligament meet), dactylitis (a type of inflammation in the fingers and toes that can result in a swollen, sausage-like appearance), axial disease and the skin lesions associated with plaque psoriasis (PsO)20,3,4 The disease causes pain, stiffness and swelling in and around the joints; it commonly appears between the ages of 30 and 50, but can develop at any age.21Nearly half of patients with PsA experience moderate fatigue and about one-third suffer from severe fatigue as measured by the modified fatigue severity scale.22 In patients with PsA, comorbidities such as obesity, cardiovascular disease, anxiety and depression are often present.23 Studies show up to 30% of people with plaque PsO also develop PsA.5,6

About ICOTYDE® (icotrokinra)

ICOTYDE® (icotrokinra) is the only targeted oral peptide designed to precisely block the IL-23 receptor, which underpins the inflammatory response in moderate-to-severe plaque PsO.1,24,25 ICOTYDE binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, precise inhibition of IL-23 signaling in human T cells.26 Clinical significance of these findings is unknown.

ICOTYDE is currently approved in the U.S. for the treatment of moderate-to-severe plaque PsO in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. Patients on ICOTYDE take one pill, once daily upon waking with water on an empty stomach, at least 30 minutes before eating.27

ICOTYDE was jointly discovered and is being developed pursuant to the license and collaboration agreement between Protagonist and Johnson & Johnson. Johnson & Johnson retains exclusive worldwide rights to develop ICOTYDE in Phase 2 clinical trials and beyond, and to commercialize compounds derived from the research conducted pursuant to the agreement against a broad range of indications.28,29,30

ICOTYDE is also being studied in active psoriatic arthritis, moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease. 12,13,14

ICOTYDE INDICATION AND IMPORTANT SAFETY INFORMATION

WHAT IS ICOTYDE (icotrokinra)?

ICOTYDE 200 mg is a prescription medicine used to treat moderate to severe plaque psoriasis in adults and children 12 years of age and older who weigh at least 88 pounds (40 kg), who may benefit from taking injections or medicines by mouth (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ICOTYDE?

  • Infections. Medicines that interact with the immune system, such as ICOTYDE, may lower your ability to fight infections and may increase your risk of infections. Your healthcare provider may check you for infections and tuberculosis (TB) before starting treatment and may treat you for TB before you begin treatment with ICOTYDE if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ICOTYDE.
    Tell your healthcare provider right away if you have any infection or have symptoms of an infection, including:
    • fever, sweat, or chills
    • cough
    • shortness of breath
    • blood in your mucus (phlegm)
    • muscle aches
    • warm, red, or painful skin or sores on your body different from your psoriasis
    • weight loss
    • diarrhea or stomach pain
    • burning when urinate or urinating more often than normal

Before taking ICOTYDE, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection that does not go away or that keeps coming back.

  • have tuberculosis (TB) or have been in close contact with someone with TB.

  • have recently received or are scheduled to receive an immunization (vaccine). Avoid receiving live vaccines during treatment with ICOTYDE.

  • have kidney problems.

  • are pregnant or plan to become pregnant. It is not known if ICOTYDE can harm your unborn baby.

  • Pregnancy Safety Study. There is a pregnancy safety study for women who take ICOTYDE during pregnancy. The purpose of this study is to collect information about the health of you and your baby. If you are pregnant or become pregnant during treatment with ICOTYDE, you can report your pregnancy by calling 1-800-526-7736 or visiting www.ICOTYDE.com.

  • are breastfeeding or plan to breastfeed. It is not known if ICOTYDE passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with ICOTYDE.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of ICOTYDE?

ICOTYDE may cause serious side effects. See “What is the most important information I should know about ICOTYDE?”

The most common side effects of ICOTYDE include:

  • headache
  • nausea
  • cough
  • fungal infection
  • tiredness

These are not all the possible side effects of ICOTYDE. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch , or call 1-800-FDA-1088.

How should I take ICOTYDE?

  • Take ICOTYDE exactly as your healthcare provider tells you to take it.
  • Take ICOTYDE 1 time a day when you wake up on an empty stomach with water. Wait at least 30 minutes after taking ICOTYDE before eating food.
  • If you have difficulty swallowing tablets, ICOTYDE can be dispersed in water. For more information, please read the Medication Guide .
  • If you miss a dose of ICOTYDE, take the dose as soon as you remember and go back to your regular schedule the next day.

Please read the full Prescribing Information , including Medication Guide , for ICOTYDE and discuss any questions that you have with your doctor.
cp-564097v2

About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.

Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com . Follow us at @JNJInnovMed.

Janssen Biotech, Inc. is a Johnson & Johnson company.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding ICOTYDE (icotrokinra). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov , www.jnj.com , investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

# # #

REFERENCES

1 Bissonnette R, et al. Data presentation. A phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis: FRONTIER 1. Presented at WCD 2023, July 3-8.
2 Mitsumasa K, et al. Data presentation. Icotrokinra, a Targeted Oral Peptide, in Biologic-Naïve Participants With Active Psoriatic Arthritis: Results Through Week 24 of a Phase 3, Randomized, DoubleBlind, Placebo-Controlled Study. Late-breaking research presentation (Abstract #LB12) at the American College of Rheumatology (ACR) Convergence 2026. November 2026.
3 Belasco J., Wei N. Psoriatic Arthritis: What is Happening at the Joint? Rheumatol Ther. 2019 Sep;6(3):305-315. Available at: https://pubmed.ncbi.nlm.nih.gov/31102105/ . Accessed November 2026.
4 Gower, T. Enthesitis and PsA. Arthritis Foundation. Available at: https://www.arthritis.org/health-wellness/about-arthritis/related-conditions/physical-effects/enthe . Accessed November 2026.
5 National Psoriasis Foundation. Are You at Risk for Psoriatic Arthritis? https://www.psoriasis.org/risk-for-psoriatic-arthritis/

6 Arthritis Foundation. 11 Things to Know About Psoriatic Arthritis. https://www.arthritis.org/diseases/more-about/11-things-to-know-about-psoriatic-arthritis

7 National Psoriasis Foundation. About Psoriatic Arthritis. Available at: https://www.psoriasis.org/about-psoriatic-arthritis/ . Accessed November 2026.
8 Ogdie, A., Coates, L. C., & Mease, P. (2020). Measuring outcomes in psoriatic arthritis. Arthritis Care & Research, 72(S10), 82–109. https://doi.org/10.1002/acr.24242 . Accessed November 2026.
9 Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015 Feb;26(1):23-31. doi: 10.3109/09546634.2013.865009. Epub 2013 Dec 20. PMID: 24354461. Accessed November 2026.
10 Thompson Jr, D. How the Psoriasis Area and Severity Index works. Everyday Health. Available at: https://www.everydayhealth.com/psoriasis/living-with/how-the-pasi-index-works . Accessed November 2026.
11 Clinicaltrials.gov. A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis (ICONIC-PsA 1). Identifier NCT06878404. https://clinicaltrials.gov/study/NCT06878404 . Accessed November 2026.
12 Clinicaltrials.gov. A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis (ICONIC-PsA 2). Identifier NCT06807424. https://clinicaltrials.gov/study/NCT06807424 . Accessed November 2026.
13 Clinicaltrials.gov. A study of JNJ-2113 in adolescent and adult participants with moderate-to-severe plaque psoriasis (ICONIC-LEAD). Identifier NCT06095115. https://classic.clinicaltrials.gov/ct2/show/NCT06095115 . Accessed November 2026.
14 Clinicaltrials.gov. A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles of the feet) (ICONIC-TOTAL). Identifier NCT06095102. https://classic.clinicaltrials.gov/ct2/show/NCT06095102 . Accessed November 2026.
15 Clinicaltrials.gov. A Study of JNJ-77242113 for the Treatment of Participants With Moderate-to-severe Plaque Psoriasis. Identifier NCT06143878. https://clinicaltrials.gov/study/NCT06143878?term=jnj-77242113&rank=10 . Accessed November 2026.
16 Clinicaltrials.gov. A Study of JNJ-77242113 for the Treatment of Participants With Moderate-to-severe Plaque Psoriasis (ICONIC-ADVANCE 2). Identifier NCT06220604. Accessed November 2026.
17 Clinicaltrials.gov. A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate-to-severe Plaque Psoriasis (ICONIC-ASCEND). Identifier NCT06934226. https://clinicaltrials.gov/study/NCT06934226 . Accessed November 2026.
18 Clinicaltrials.gov. A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis (ICONIC-UC). Identifier NCT07196748. https://clinicaltrials.gov/study/NCT07196748 . Accessed November 2026.
19 Clinicaltrials.gov. A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn’s Disease (ICONIC-CD). Identifier NCT07196722. https://clinicaltrials.gov/study/NCT07196722 . Accessed November 2026.
20 Donvito T., CreakyJoints: What Is Dactylitis? The ‘Sausage Finger’ Swelling You Should Know About. Accessed November 2026.
21 National Psoriasis Foundation. About Psoriatic Arthritis. Available at: https://www.psoriasis.org/about-psoriatic-arthritis/ . Accessed November 2026.
22 Husted J.A., et al. Occurrence and correlates of fatigue in psoriatic arthritis. Ann Rheum Dis, 2008:68(10), 1553–1558. Available at: https://doi.org/10.1136/ard.2008.098202 . Accessed November 2026.
23 Haddad A., Zisman D. Comorbidities in Patients with Psoriatic Arthritis. Rambam Maimonides Med J 2017 Jan 30;8(1):e0004. Available at: https://doi.org/10.5041/RMMJ.10279 . Accessed November 2026.
24 Razawy W, et al. The role of IL‐23 receptor signaling in inflammation‐mediated erosive autoimmune arthritis and bone remodeling. Eur J Immunol. 2018 Feb; 48(2): 220–229. Accessed November 2026.
25 Tang C, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012 Feb; 135(2): 112–124. Accessed November 2026.
26 Pinter A, et al. Data Presentation. JNJ-77242113 Treatment Induces a Strong Systemic Pharmacodynamic Response Versus Placebo in Serum Samples of Patients with Plaque Psoriasis: Results from the Phase 2, FRONTIER 1 Study. Presented at EADV 2023, October 11-14.
27 ICOTYDE® prescribing information.
28 Protagonist Therapeutics. Press release. Protagonist Therapeutics announces amendment of agreement with Janssen Biotech for the continued development and commercialization of IL-23 antagonists. Available at: https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-amendment-of-agreement-with-janssen-biotech-for-the-continued-development-and-commercialization-of-il-23-antagonists-301343621.html . Accessed November 2026.
29 Protagonist Therapeutics. Press release. Protagonist Reports positive results from Phase 1 and pre-clinical studies of oral Interleukin-23 receptor antagonist JNJ-2113. Available at: https://www.prnewswire.com/news-releases/protagonist-reports-positive-results-from-phase-1-and-pre-clinical-studies-of-oral-interleukin-23-receptor-antagonist-jnj-2113-301823039.html . Accessed November 2026.
30 Protagonist Therapeutics. Press release. Protagonist Therapeutics announces positive topline results for Phase 2b FRONTIER 1 clinical trial of oral IL-23 receptor antagonist JNJ-2113 (PN-235) in psoriasis. Available at: https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-positive-topline-results-for-phase-2b-frontier-1-clinical-trial-of-oral-il-23-receptor-antagonist-jnj-2113-pn-235-in-psoriasis-301764181.html . Accessed November 2026.

Media contact:
Meg Farina
[email protected]

Investor contact:
Jessica Margevich
[email protected]

Rheumatology Immunology

Back to top

johnson-johnson-logo-white-1.svg

This website is intended for U.S. audiences only.
Do not sell or share my personal information

Limit the use of my sensitive personal information

© Johnson & Johnson and its affiliates 2026

Company Logo

Cookie Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Manage Consent Preferences

Strictly necessary cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you, which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will then not work.

Cookies Details

Functional cookies

Functional cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by Third-party providers whose services we have added to our pages. If you do not allow these cookies, then some or all of these services may not function properly.

Cookies Details

Performance cookies

Performance cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. If you do not allow these cookies, we will not know when you have visited our site and will not be able to monitor its performance. You can set your browser to block or alert you about these cookies.

Cookies Details

Media cookies

Media cookies

These cookies are set by a range of media services that we have added to the site to enable the display of media content, such as embedded videos. Some of these cookies are necessary for the proper display of the media content. Some media services also place cookies that are capable of tracking your usage of the media service and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see such media services, such as videos.

Please note that Google may automatically deploy YouTube cookies outside of our control. To find out how to manage Google and YouTube preferences and cookies, please visit https://policies.google.com/technologies/cookies#how-google-uses-cookies

Cookies Details

Targeting cookies

Targeting cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookies Details

Back Button

Cookie List

Search Icon

Filter Icon

Clear

  • checkbox label label

Apply Cancel

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Allow All Confirm My Choices

Powered by Onetrust

· New patient experience dataa to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain

· Patient insights complement Phase 2 study results demonstrating a 50% increase in saliva productionb in more than twice as many patients on nipocalimab compared to placeboc

· Two Phase 3 studies are ongoing, evaluating nipocalimab in Sjögren’s disease including these measures critical to patients

November 7, 2026

November 7, 2026

Share

New Brunswick, NJ. (November 7, 2026) – Johnson & Johnson (NYSE: JNJ) today announced new patient experience findingsa from the Phase 2 DAHLIAS study of nipocalimab in Sjögren’s disease (SjD), a chronic, systemic autoantibody-driven disease affecting approximately four million people worldwide.1 The results show that mouth dryness is the symptom improvement that matters most to patients,2 complementing previously reported Phase 2 study results on increased saliva production in patients who received nipocalimab.3 This was also the most frequently reported symptom, with 96% of patients surveyed citing mouth dryness.2 These findings helped to inform the design of the ongoing Phase 3 study of nipocalimab in SjD, and are among 23 abstracts on nipocalimab to be presented at the American College of Rheumatology (ACR) Convergence 2026.

Patient experience of Sjögren’s disease reflects core symptoms including dryness and systemic manifestations

Interviews were conducted with participants following the Phase 2 study’s treatment period. Five core symptoms were most frequently reported by patients: mouth dryness (96%), fatigue (92%), eye dryness (90%), joint pain (73%) and, among women, vaginal dryness (49%). Patients who participated in the interviews reported improvements across many of these core symptoms during the treatment phase of the study.2

“Patients told us that Sjögren’s disease affects nearly every aspect of daily life, with mouth dryness emerging as both the most frequently reported symptom and the symptom most often prioritized, among those asked, for improvement,” said Ghaith Noaiseh, M.D., Associate Professor, Allergy, Clinical Immunology, and Rheumatology, The University of Kansas Medical Center.d “Notably, in the previously published clinical data, at least 50% improvement in objective salivary flow was observed in more than twice as many patients receiving 15 mg/kg nipocalimab compared with placebo.c I look forward to the Phase 3 results and what they may tell us about the potential of nipocalimab to deliver meaningful benefit for patients.”

Symptom improvements were associated with tangible improvements in everyday life and functioning

Patients described the core symptoms of SjD as having far-reaching effects on physical, social and emotional well-being, with improvements in these symptoms reported to have tangible benefits in day-to-day life. These improvements are associated with positive changes in physical functioning, less need for disease management, and less interference in family, work and social commitments. Nearly three-quarters of participants (73.5%) reported being satisfied or very satisfied with study treatment.2

“These patient insights reinforce the broad, systemic nature of Sjögren’s disease and the importance of recognizing and addressing the symptoms and outcomes that matter most to patients,” said Leonard L. Dragone, M.D., Ph.D., Disease Area Leader, Autoantibody and Rheumatology, Johnson & Johnson. “Together, these findings alongside the positive Phase 2 clinical results provide important context as we advance nipocalimab as a potential targeted approach designed to address the underlying biology of this serious autoantibody-driven disease.”

Following the positive Phase 2 DAHLIAS results, which showed nipocalimab significantly reduced disease activity and severity in patients with moderate-to-severe disease, Johnson & Johnson initiated the Phase 3 DAFFODIL study in adults with moderate-to-severe SjD.3 The DAFFODIL study design reflects the need to address both the systemic nature of SjD and the outcomes patients value most by assessing disease activity alongside dryness, pain, fatigue, quality of life and patient-perceived improvement.4

Nipocalimab is the only Fc receptor (FcRn) blocker granted both Breakthrough Therapy Designation and Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of adults with moderate-to-severe SjD.

Editor’s notes:

a. Of 163 DAHLIAS participants, 49 (30.1%) – still blinded and pooled across treatment arms – completed the exit interviews. The analysis was based on 60-minute, one-to-one semi-structured qualitative exit interviews conducted within two weeks after the 24-week treatment period, using blinded, independent researchers and thematic analysis to systematically capture patient experience and perceived symptom changes.
b. Objective unstimulated salivary flow, an exploratory endpoint of the Phase 2 DAHLIAS study.
c. Data from the Phase 2 DAHLIAS study show an improvement in objective salivary flow (i.e., at least 50% increase from baseline) was observed in more than twice as many patients in the high-dose nipocalimab group (15 mg/kg) compared to the placebo group (33% versus 16%, respectively) at Week 24.
d. Ghaith Noaiseh, M.D., is a paid consultant for Johnson & Johnson. He has not been compensated for any media work.

About DAHLIAS

DAHLIAS (NCT04968912 ) is a Phase 2 multicenter, randomized, placebo-controlled, double-blind, dose-ranging study to evaluate the effects of nipocalimab in participants with moderately-to-severely active primary SjD who were seropositive for anti-Ro60 and/or anti-Ro52 immunoglobulin G (IgG) antibodies. 163 adults aged 18-75 were randomized 1:1:1 to receive intravenous nipocalimab at 5 or 15 mg/kg, or placebo every 2 weeks through Week 22 and received protocol-permitted background standard of care. Safety assessments were conducted through Week 30. The primary endpoint was change from baseline in the ClinESSDAI (Clinical European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index) Score at Week 24.5

About Sjögren’s disease

Sjögren’s disease (SjD) is one of the most prevalent autoantibody-driven diseases for which no therapies are currently approved that treat the underlying and systemic nature of the disease.6 It is a chronic autoantibody-driven disease that is estimated to impact approximately four million people worldwide and is nine times more common in women than men.1 SjD is characterized by autoantibody production, chronic inflammation, and lymphocytic infiltration of exocrine glands.7 Most patients are affected by mucosal dryness (eyes, mouth, vagina), joint pain and fatigue.8 More than 50% of SjD patients have a moderate-to-severe form of the condition, and cumulative disease burden can be as high as that of rheumatoid arthritis or systemic lupus erythematosus.9,10,11 It is usually associated with impaired quality of life and, in up to approximately half of patients, a loss of functional capacity that can result in an inability to work due to a disability.8,9,12

About nipocalimab

Nipocalimab is an investigational immunoselective treatment designed to target, bind with high affinity, and block the neonatal Fc receptor (FcRn), reducing circulating immunoglobulin (IgG) antibodies that drive disease while also preserving B-cell function based on in vitro and/or in vivo studies.[13],[14] Nipocalimab is being investigated across three key segments in the autoantibody space including Rheumatologic disease, Rare Autoantibody diseases, and Maternal Fetal diseases mediated by maternal alloantibodies in which blockade of IgG binding to FcRn in the placenta is believed to limit transplacental transfer of maternal alloantibodies to the fetus.4,15,16,17,18,19,20,21,22

The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted several key designations to nipocalimab including:

  • EU EMA Orphan medicinal product designation for hemolytic disease of the fetus and newborn (HDFN) in October 2019 and fetal and neonatal alloimmune thrombocytopenia (FNAIT) in April 2025
  • U.S. FDA Fast Track designation in HDFN and warm autoimmune hemolytic anemia (wAIHA) in July 2019, generalized myasthenia gravis (gMG) in December 2021, FNAIT in March 2024, Sjögren’s disease (SjD) in March 2025, and systemic lupus erythematosus (SLE) in January 2026
  • U.S. FDA Orphan drug status for wAIHA in December 2019, HDFN in June 2020, gMG in February 2021, chronic inflammatory demyelinating polyneuropathy (CIDP) in October 2021 and FNAIT in December 2023
  • U.S. FDA Breakthrough Therapy designation for HDFN in February 2024 and for SjD in November 2024
  • U.S. FDA granted Priority Review in gMG in Q4 2024 and wAIHA in Q2 2026

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.

Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com

Follow us at @JNJInnovMed .

Janssen Biotech, Inc. is a Johnson & Johnson company.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of nipocalimab. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

# # #

REFERENCES

1Beydon, M., et al. Epidemiology of Sjögren syndrome. Nat Rev Rheumatol. 2024 Mar;20(3):158-169. doi: 10.1038/s41584-023-01057-6.
2 Noaiseh G., et al. Assessing the Patient Experience of Nipocalimab: Exit Interviews from the Phase 2 Randomized Placebo Controlled Study in Sjogren’s Disease. Abstract #1366
3 Noaiseh, G et al., Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren’s disease (DAHLIAS): A randomised, phase 2, placebo-controlled, double-blind trial. The Lancet. Oct 2025; Nov 22;406(10518):2435-2448.
4 ClinicalTrials.gov Identifier: NCT06741969. Available at: https://clinicaltrials.gov/study/NCT06741969 . Last accessed: November 2026.
5 ClinicalTrials.gov Identifier: NCT04968912. Available at: https://clinicaltrials.gov/study/NCT04968912 . Last accessed: November 2026.
6 Huang H, et al. Mortality in patients with primary Sjögren’s syndrome: a systematic review and meta-analysis. Rheumatology (Oxford). 2021 Sep 1;60(9):4029-4038. doi: 10.1093/rheumatology/keab364. PMID: 33878179
7 Meudec L, Nocturne G, Mariette X. Update on the Aetiopathogenesis of Sjögren Disease: From Interferon Signaling to Epithelial Dysfunction. J Clin Med. 2026 Mar 4;15(5):1945. doi: 10.3390/jcm15051945
8 Mayo Clinic. Sjogren’s syndrome. Available at: https://www.mayoclinic.org/diseases-conditions/sjogrens-syndrome/symptoms-causes/syc-20353216 . Last accessed: November 2026.
9 Lim ZFS, et al. Regulatory T cell therapy for Sjögren’s disease: From pathogenesis to targeted treatment. J Transl Autoimmun. 2025 Aug 26;11:100311. doi: 10.1016/j.jtauto.2025.100311.
10 Carsons SE, Patel BC. Sjogren Syndrome. [Updated 2023 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK431049/

11 Hackett KL, et al. Impaired functional status in primary Sjögren’s syndrome. Arthritis Care Res (Hoboken). 2012 Nov;64(11):1760-4.
12 Meijer JM, et al. Health-related quality of life, employment and disability in patients with Sjogren’s syndrome. Rheumatology (Oxford). 2009 Sep;48(9):1077-82. doi: 10.1093/rheumatology/kep141. Epub 2009 Jun 24. PMID: 19553376.
13 Ling LE., et al. M281, an anti‐fcrn antibody: Pharmacodynamics, pharmacokinetics, and safety across the full range of IGG reduction in a first‐in‐human study. Clinical Pharmacology & Therapeutics., 2018;105;4:1031–1039. Available at: https://doi.org/10.1002/cpt.1276 .
14 National Institute of Arthritis and Musculoskeletal and Skin Disease. (2022) Systemic Lupus Erythematosus (Lupus). https://www.niams.nih.gov/health-topics/lupus . Last accessed: November 2026.
15 ClinicalTrials.gov Identifier: NCT04951622. Available at: https://clinicaltrials.gov/ct2/show/NCT04951622 . Last accessed: November 2026.
16 ClinicalTrials.gov. NCT03842189. Available at: https://clinicaltrials.gov/ct2/show/NCT03842189 . Last accessed: November 2026.
17 ClinicalTrials.gov Identifier: NCT05327114. Available at: https://www.clinicaltrials.gov/study/NCT05327114 . Last accessed: November 2026.
18 ClinicalTrials.gov Identifier: NCT05379634. Available at: https://clinicaltrials.gov/study/NCT05379634 . Last accessed: November 2026.
19 ClinicalTrials.gov Identifier: NCT05912517. Available at: https://www.clinicaltrials.gov/study/NCT05912517 . Last accessed: November 2026.
20 ClinicalTrials.gov Identifier: NCT04882878. Available at: https://clinicaltrials.gov/study/NCT04882878 . Last accessed: November 2026.
21 ClinicalTrials.gov Identifier: NCT06449651. Available at: https://clinicaltrials.gov/study/NCT06449651 . Last accessed: November 2026.
22 ClinicalTrials.gov Identifier: NCT06533098 Available at: https://clinicaltrials.gov/study/NCT06533098 . Last accessed: November 2026.

Media contact:
Bridget Kimmel
[email protected]

Investor contact:
Jess Margevich
[email protected]

Immunology Rheumatology Autoantibody

Back to top

johnson-johnson-logo-white-1.svg

This website is intended for U.S. audiences only.
Do not sell or share my personal information

Limit the use of my sensitive personal information

© Johnson & Johnson and its affiliates 2026

Company Logo

Cookie Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Manage Consent Preferences

Strictly necessary cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you, which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will then not work.

Cookies Details

Functional cookies

Functional cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by Third-party providers whose services we have added to our pages. If you do not allow these cookies, then some or all of these services may not function properly.

Cookies Details

Performance cookies

Performance cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. If you do not allow these cookies, we will not know when you have visited our site and will not be able to monitor its performance. You can set your browser to block or alert you about these cookies.

Cookies Details

Media cookies

Media cookies

These cookies are set by a range of media services that we have added to the site to enable the display of media content, such as embedded videos. Some of these cookies are necessary for the proper display of the media content. Some media services also place cookies that are capable of tracking your usage of the media service and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see such media services, such as videos.

Please note that Google may automatically deploy YouTube cookies outside of our control. To find out how to manage Google and YouTube preferences and cookies, please visit https://policies.google.com/technologies/cookies#how-google-uses-cookies

Cookies Details

Targeting cookies

Targeting cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookies Details

Back Button

Cookie List

Search Icon

Filter Icon

Clear

  • checkbox label label

Apply Cancel

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Allow All Confirm My Choices

Powered by Onetrust

Innovative Medicine Bull 0 Bear 0 Routine

Load more

Back to top

johnson-johnson-logo-white-1.svg

This website is intended for U.S. audiences only.
Do not sell or share my personal information

Limit the use of my sensitive personal information

© Johnson & Johnson and its affiliates 2026

Company Logo

Cookie Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Manage Consent Preferences

Strictly necessary cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you, which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will then not work.

Cookies Details

Functional cookies

Functional cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by Third-party providers whose services we have added to our pages. If you do not allow these cookies, then some or all of these services may not function properly.

Cookies Details

Performance cookies

Performance cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. If you do not allow these cookies, we will not know when you have visited our site and will not be able to monitor its performance. You can set your browser to block or alert you about these cookies.

Cookies Details

Media cookies

Media cookies

These cookies are set by a range of media services that we have added to the site to enable the display of media content, such as embedded videos. Some of these cookies are necessary for the proper display of the media content. Some media services also place cookies that are capable of tracking your usage of the media service and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see such media services, such as videos.

Please note that Google may automatically deploy YouTube cookies outside of our control. To find out how to manage Google and YouTube preferences and cookies, please visit https://policies.google.com/technologies/cookies#how-google-uses-cookies

Cookies Details

Targeting cookies

Targeting cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookies Details

Back Button

Cookie List

Search Icon

Filter Icon

Clear

  • checkbox label label

Apply Cancel

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Allow All Confirm My Choices

Powered by Onetrust

Prompts

Johnson & Johnson (ticker JNJ), listed in United States.

ETFs Holding Johnson & Johnson

ETF Weight in ETF Shares Market value As of
GDOC 8.31% 6,127 $ 1.629M Aug 31, 2026
PINK 7.88% 94,658 $ 26.381M Nov 17, 2026
MEDX 5.59% 4,200 $ 1.067M Jun 30, 2026
DIVL 5.49% 12,987 $ 3.298M Jun 30, 2026
EASY 5.28% 12,546 $ 3.216M Jul 31, 2026
PSIL 5.00% 6,842 $ 1.907M Nov 17, 2026
FCTE 4.94% 47,534 $ 12.072M Jun 30, 2026
DUNK 4.93% 28,907 $ 8.168M Nov 17, 2026
DIVZ 4.83% 50,803 $ 12.902M Jun 30, 2026
JDOC 4.76% 1,689 $ 470.724K Nov 17, 2026
UDI 4.54% 727 $ 184.636K Jun 30, 2026
CCOR 4.54% 4,942 $ 1.267M Jul 31, 2026
QLTY 4.38% 853,823 $ 226.989M Aug 31, 2026
AGQI 4.11% 7,449 $ 2.105M Nov 16, 2026
RFFC 3.91% 4,793 $ 1.274M Aug 31, 2026
HRTS 3.90% 8,166 $ 2.171M Aug 31, 2026
SEIQ 3.90% 101,965 $ 25.896M Jun 30, 2026
YOKE 3.74% 29,566 $ 8.24M Nov 18, 2026
JPEF 3.57% 247,594 $ 69.004M Nov 17, 2026
MDLV 3.47% 6,005 $ 1.67M Nov 18, 2026
SEPI 3.44% 20,651 $ 5.245M Jun 30, 2026
TBG 3.41% 40,834 $ 11.38M Nov 18, 2026
TGLR 3.38% 4,984 $ 1.278M Jul 31, 2026
GDIV 3.30% 27,846 $ 7.957M Nov 13, 2026
NPFE 3.25% 82,446 $ 21.135M Jul 31, 2026
BDIV 3.24% 843 $ 216.103K Jul 31, 2026
USMC 3.20% 439,492 $ 111.618M Jun 30, 2026
RFDA 3.18% 9,843 $ 2.617M Aug 31, 2026
SELV 3.14% 30,280 $ 7.69M Jun 30, 2026
CANC 3.09% 24,555 $ 6.528M Aug 31, 2026
ACEP 3.04% 10,749 $ 3M Nov 18, 2026
ASLV 3.02% 25,764 $ 6.605M Jul 31, 2026
FRIZ 3.01% 621 $ 157.715K Jun 30, 2026
DIVS 2.97% 4,493 $ 1.141M Jun 30, 2026
FLV 2.96% 42,499 $ 11.298M Aug 31, 2026
CAPE 2.81% 26,392 $ 6.703M Jun 30, 2026
RJDI 2.77% 10,960 $ 2.784M Jun 30, 2026
SIXA 2.77% 55,587 $ 15.76M Nov 12, 2026
BKDV 2.76% 197,773 $ 50.699M Jul 31, 2026
LOTI 2.75% 5,042 $ 1.293M Jul 31, 2026
BAMG 2.68% 12,886 $ 3.426M Aug 31, 2026
GEND 2.57% 487 $ 124.842K Jul 31, 2026
KOOL 2.54% 5,846 $ 1.485M Jun 30, 2026
BBLU 2.54% 44,937 $ 12.52M Nov 18, 2026
SEIM 2.48% 146,664 $ 37.248M Jun 30, 2026
SPCT 2.48% 6,507 $ 1.668M Jul 31, 2026
SAMM 2.45% 2,929 $ 743.878K Jun 30, 2026
ACVU 2.43% 24,208 $ 0.00 Nov 18, 2026
AVIE 2.43% 1,433 $ 404.894K Nov 16, 2026
SCLZ 2.43% 1,873 $ 475.686K Jun 30, 2026
KONG 2.42% 2,072 $ 526.226K Jun 30, 2026
DVND 2.37% 4,910 $ 1.247M Jun 30, 2026
BLCV 2.36% 29,966 $ 8.467M Nov 16, 2026
BRCE 2.34% 3,261 $ 866.937K Aug 31, 2026
THRO 2.31% 850,652 $ 240.352M Nov 16, 2026
BDVG 2.30% 1,227 $ 311.621K Jun 30, 2026
DFVX 2.20% 44,567 $ 12.636M Nov 12, 2026
SAMT 2.18% 75,256 $ 19.113M Jun 30, 2026
AQEC 2.14% 48,413 $ 12.295M Jun 30, 2026
FDIV 2.10% 4,815 $ 1.234M Jul 31, 2026
OEI 2.08% 3,759 $ 963.62K Jul 31, 2026
SPIN 2.04% 3,211 $ 907.268K Nov 16, 2026
PRMR 2.03% 7,007 $ 1.863M Aug 31, 2026
GMOV 2.01% 8,091 $ 2.151M Aug 31, 2026
HGRO 2.00% 9,843 $ 2.523M Jul 31, 2026
FLCV 1.99% 10,426 $ 2.772M Aug 31, 2026
VUS 1.96% 1,368 $ 350.687K Jul 31, 2026
YLDE 1.94% 12,336 $ 3.133M Jun 30, 2026
DYNF 1.92% 2,798,671 $ 790.764M Nov 16, 2026
LCF 1.90% 4,850 $ 1.232M Jun 30, 2026
LSEQ 1.90% 1,130 $ 322.898K Nov 13, 2026
ZECP 1.87% 26,474 $ 7.038M Aug 31, 2026
INFO 1.80% 60,802 $ 17.374M Nov 13, 2026
FFLV 1.76% 1,131 $ 289.932K Jul 31, 2026
DFUV 1.75% 964,984 $ 273.592M Nov 12, 2026
JEPI 1.72% 2,849,821 $ 794.245M Nov 17, 2026
PY 1.72% 14,890 $ 3.782M Jun 30, 2026
TVAL 1.70% 68,749 $ 19.425M Nov 17, 2026
BIGY 1.68% 1,662 $ 469.598K Nov 17, 2026
GOP 1.66% 5,119 $ 1.446M Nov 17, 2026
NANC 1.65% 15,848 $ 4.478M Nov 17, 2026
VFMV 1.65% 28,040 $ 7.454M Aug 31, 2026
MFSV 1.62% 36,695 $ 9.755M Aug 31, 2026
XMAG 1.59% 12,088 $ 3.427M Nov 13, 2026
JDIV 1.58% 698 $ 194.533K Nov 17, 2026
UPSD 1.55% 7,056 $ 1.809M Jul 31, 2026
LVDS 1.51% 6,472 $ 1.804M Nov 17, 2026
SFTY 1.51% 44,694 $ 11.882M Aug 31, 2026
STOX 1.49% 12,582 $ 3.345M Aug 31, 2026
HELO 1.49% 254,591 $ 70.955M Nov 17, 2026
BUSA 1.47% 17,327 $ 4.401M Jun 30, 2026
PHEQ 1.45% 8,013 $ 2.035M Jun 30, 2026
JAVA 1.43% 383,344 $ 106.838M Nov 17, 2026
ATFV 1.38% 10,764 $ 2.734M Jun 30, 2026
NQLT 1.37% 2,526 $ 671.537K Aug 31, 2026
NBGX 1.35% 756 $ 200.983K Aug 31, 2026
JUSA 1.34% 42,029 $ 11.713M Nov 17, 2026
FFND 1.32% 4,901 $ 1.303M Aug 31, 2026
MODL 1.31% 52,657 $ 13.373M Jun 30, 2026
JGRO 1.30% 418,033 $ 116.506M Nov 17, 2026